​

Theravance Biopharma (TBPH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TBPH Stock Forecast

Theravance Biopharma (TBPH) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $12.50, with a high of $15.00 and a low of $10.00. This represents a 29.80% increase from the last price of $9.63.

$8 $9 $10 $11 $12 $13 $14 $15 High: $15 Avg: $12.5 Low: $10 Last Closed Price: $9.63

TBPH Stock Rating

Theravance Biopharma stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (66.67%), 2 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 2 4 0 Strong Sell Sell Hold Buy Strong Buy

TBPH Forecast vs Benchmarks

TypeNameUpside
StockTheravance Biopharma29.80%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-13
Avg Price Target-$10.00$15.33
Last Closing Price$9.63$9.63$9.63
Upside/Downside-3.84%59.19%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25113--5
Dec, 24113--5
Nov, 241332110
Oct, 241332110
Sep, 241332110
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 13, 2024David RisingerLeerink Partners$10.00$7.6630.55%3.84%
Aug 06, 2024Douglas TsaoH.C. Wainwright$15.00$9.5956.41%55.76%
Apr 12, 2024Julian HarrisonBTIG$21.00$8.93135.16%118.07%
Nov 17, 2022Leerink Partners$14.00$11.2224.78%45.38%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024Leerink PartnersMarket PerformMarket Performhold
Sep 16, 2024Leerink PartnersMarket PerformMarket Performhold
Sep 16, 2024H.C. WainwrightBuyBuyhold
Aug 06, 2024Zacks Investment ResearchPositiveinitialise
Aug 06, 2024H.C. WainwrightUnderperformUnderperformhold
Aug 06, 2024Cowen & Co.HoldHoldhold
Aug 06, 2024H.C. WainwrightBuyBuyhold
May 24, 2024Cowen & Co.HoldHoldhold
Apr 12, 2024BTIGBuyinitialise
Nov 17, 2022SVB LeerinkOutperformOutperformhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.46$-2.87$-1.26$-1.00-----
Avg Forecast$-4.51$-2.67$-0.55$-0.97$-1.06$0.43$-0.09$0.19$0.36
High Forecast$-6.15$-3.64$-0.79$-1.01$-1.24$0.31$-1.39$-0.61$0.27
Low Forecast$-3.35$-1.98$-0.42$-0.88$-0.85$0.57$1.07$0.80$0.49
Surprise %-1.11%7.49%129.09%3.09%-----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$71.86M$55.31M$51.35M$57.42M-----
Avg Forecast$73.90M$53.67M$51.65M$57.46M$62.60M$97.68M$98.72M$117.52M$173.64M
High Forecast$59.21M$43.00M$41.70M$57.05M$48.92M$82.55M$80.66M$96.03M$141.88M
Low Forecast$94.53M$68.65M$68.24M$57.95M$88.30M$116.30M$125.16M$149.00M$220.14M
Surprise %-2.76%3.06%-0.59%-0.06%-----

Net Income Forecast

$-300M $-220M $-140M $-60M $20M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-278.02M$-199.43M$-92.82M$-55.19M-----
Avg Forecast$-178.32M$-191.10M$-170.64M$-55.19M$-49.40M$24.20M$-3.32M$10.41M$19.91M
High Forecast$-213.99M$-229.32M$-204.77M$-66.23M$-68.63M$17.08M$-76.87M$-33.73M$15.18M
Low Forecast$-142.66M$-152.88M$-136.52M$-44.15M$-47.18M$31.32M$59.17M$44.24M$26.84M
Surprise %55.91%4.36%-45.60%------

TBPH Forecast FAQ

Is Theravance Biopharma stock a buy?

Theravance Biopharma stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Theravance Biopharma is a favorable investment for most analysts.

What is Theravance Biopharma's price target?

Theravance Biopharma's price target, set by 6 Wall Street analysts, averages $12.5 over the next 12 months. The price target range spans from $10 at the low end to $15 at the high end, suggesting a potential 29.80% change from the previous close price of $9.63.

How does Theravance Biopharma stock forecast compare to the average forecast of its sector, industry, and investment themes?

Theravance Biopharma stock forecast shows a 29.80% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Theravance Biopharma over the past three months?

  • January 2025: 20.00% Strong Buy, 20.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 20.00% Strong Buy, 20.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 10.00% Strong Buy, 30.00% Buy, 30.00% Hold, 20.00% Sell, 10.00% Strong Sell.

What is Theravance Biopharma’s EPS forecast?

Theravance Biopharma's average annual EPS forecast for its fiscal year ending in December is -1.06 for 2024, a 6.00% increase from the reported $-1 in 2023. The prediction for 2025 is $0.43, $-0.09 for 2026, $0.19 for 2027, and $0.36 for 2028.

What is Theravance Biopharma’s revenue forecast?

Theravance Biopharma's average annual revenue forecast for its fiscal year ending in December is $62.6M for 2024, a 9.01% increase from the reported $57.42M in 2023. The forecast for 2025 is $97.68M, $98.72M for 2026, $117.52M for 2027, and $173.64M for 2028.

What is Theravance Biopharma’s net income forecast?

For its fiscal year ending in December, Theravance Biopharma's average annual net income forecast is $-49.401M for 2024, reflecting a -10.49% decrease from the reported $-55.193M in 2023. The projection for 2025 is $24.2M, $-3.317M for 2026, $10.41M for 2027, and $19.91M for 2028.